Table 1.
Efficacy of the 6 selected dugs against M. abscessus. Absolute IC10, IC20, and IC50 were obtained from dose response curves of each drug individually based on MIC assay with M. abscessus. The Cmax values were obtained from FDA regulatory documents and literatures as outlined in the Supplementary Material. The NationalClinicalTrial.gov (NCT) identifiers of trials pertaining to the administration of the corresponding drugs against NTM infections are also listed. AMK: amikacin, CLR: clarithromycin, LVX: levofloxacin, LZD: linezolid, MEM: meropenem, and RFB: rifabutin.
| Drug | (μg /mL) | (μg /mL) | |||||
|---|---|---|---|---|---|---|---|
| IC10 | IC20 | IC50 | Cmax | 5% Cmax | 10% Cmax | Clinical Trial | |
| LZD | 0.508 | 0.966 | 6.567 | 12.7 | 0.635 | 1.270 | NCT03220074 |
| AMK | 0.917 | 1.490 | 4.413 | 2.1 | 0.105 | 0.210 | NCT01315236 |
| MEM | 0.670 | 2.996 | 22.280 | 61.6 | 3.080 | 6.160 | / |
| CLR | 0.0325 | 0.0442 | 0.129 | 10 | 0.500 | 1.000 | NCT00600769 |
| RFB | 3.628 | 4.412 | 6.756 | 0.375 | 0.0188 | 0.0375 | NCT00810407 |
| LVX | 0.656 | 0.663 | 0.680 | 9.3 | 0.465 | 0.930 | NCT03220074 |